Quest Diagnostics Incorporated $DGX Shares Sold by Tidal Investments LLC

14 Sep 2026, 04:33 by Scott Moore · The Cerbat Gem

Tidal Investments LLC cut its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 33.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,698 shares of the medical research company’s stock after selling 12,366 shares during the period. Tidal Investments LLC’s holdings in Quest Diagnostics were worth $5,235,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Moneta Group Investment Advisors LLC grew its holdings in shares of Quest Diagnostics by 3.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock worth $241,000 after acquiring an additional 50 shares during the period. Ossiam boosted its position in Quest Diagnostics by 6.1% during the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock worth $202,000 after purchasing an additional 61 shares in the last quarter. Concurrent Investment Advisors LLC boosted its position in Quest Diagnostics by 1.2% during the second quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock worth $1,099,000 after purchasing an additional 62 shares in the last quarter. Independent Advisor Alliance grew its holdings in Quest Diagnostics by 1.6% in the fourth quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after purchasing an additional 66 shares during the last quarter. Finally, PFG Private Wealth Management LLC grew its holdings in Quest Diagnostics by 5.1% in the second quarter. PFG Private Wealth Management LLC now owns 1,453 shares of the medical research company’s stock valued at $308,000 after purchasing an additional 71 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DGX has been the subject of several research reports. Truist Financial lifted their price target on Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Mizuho increased their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. JPMorgan Chase & Co. raised their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Jefferies Financial Group restated a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Finally, Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $236.31.

Read Our Latest Analysis on DGX

Insider Activity at Quest Diagnostics

In related news, CEO J. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the transaction, the chief executive officer owned 122,423 shares of the company’s stock, valued at approximately $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Delaney sold 1,600 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the sale, the senior vice president owned 10,335 shares in the company, valued at approximately $2,430,585.30. This trade represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 34,277 shares of company stock valued at $8,316,493. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Stock Down 0.1%

DGX opened at $234.80 on Monday. The firm has a market cap of $25.92 billion, a P/E ratio of 24.93, a PEG ratio of 2.15 and a beta of 0.55. The business’s fifty day simple moving average is $229.71 and its 200 day simple moving average is $209.40. Quest Diagnostics Incorporated has a 52 week low of $171.18 and a 52 week high of $247.19. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be given a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s payout ratio is currently 36.52%.

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.

Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.